Search Results - "Shanks, RG"

Refine Results
  1. 1

    Cardiovascular effects of cromakalim (BRL 34915) in healthy volunteers by Fox, JS, Whitehead, EM, Shanks, RG

    Published in British journal of clinical pharmacology (01-07-1991)
    “…1. The effect of oral doses of cromakalim 0.5, 1.0, 1.5 and 2.0 mg on several cardiovascular parameters was studied in healthy male volunteers. 2. In the first…”
    Get full text
    Journal Article
  2. 2

    Effects of azepexole and clonidine on baroreceptor mediated reflex bradycardia and physiological tremor in man by Harron, DW, Riddell, JG, Shanks, RG

    Published in British journal of clinical pharmacology (01-11-1985)
    “…The effects of oral administration of azepexole 10 mg, clonidine 300 micrograms and placebo on baroreceptor mediated reflex bradycardia and physiological…”
    Get full text
    Journal Article
  3. 3

    The clinical pharmacology of mexiletine by Campbell, NP, Kelly, JG, Adgey, AA, Shanks, RG

    Published in British journal of clinical pharmacology (01-08-1978)
    “…1. Mexiletine was given to 156 patients by intravenous or oral routes of administration. 2. There was great interpatient variation in kinetics and plasma…”
    Get full text
    Journal Article
  4. 4

    Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol by Leahey, WJ, Neill, JD, Varma, MP, Shanks, RG

    Published in British journal of clinical pharmacology (01-01-1980)
    “…1 Plasma levels of propranolol were measured at intervals after the oral administration of 160 mg propranolol and 160 mg L.A. propranolol in ten subjects who…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Clinical pharmacology of vasodilatory beta-blocking drugs by Shanks, R G

    Published in The American heart journal (01-03-1991)
    “…The clinical pharmacology of beta-adrenoceptor blockers is summarized. They have a variety of pharmacological actions on the beta-adrenoceptors. For example,…”
    Get more information
    Journal Article
  7. 7

    Clinical pharmacokinetics of β-adrenoceptor antagonists: an update by RIDDELL, J. G, HARRON, D. W. G, SHANKS, R. G

    Published in Clinical pharmacokinetics (01-05-1987)
    “…The beta-adrenoceptor antagonists have been widely used clinically for over 20 years and their pharmacokinetics have been more thoroughly investigated than any…”
    Get full text
    Journal Article
  8. 8
  9. 9

    The dose dependency of the alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol in man by Tham, TC, Guy, S, McDermott, BJ, Shanks, RG, Riddell, JG

    Published in British journal of clinical pharmacology (01-07-1995)
    “…1. The alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol, a beta‐adrenoceptor antagonist with vasodilating properties, and labetalol were…”
    Get full text
    Journal Article
  10. 10

    Effects of the beta 2‐adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline‐induced beta‐adrenoceptor responses in man by Arnold, JM, O'Connor, PC, Riddell, JG, Harron, DW, Shanks, RG, McDevitt, DG

    Published in British journal of clinical pharmacology (01-05-1985)
    “…ICI 118,551, 5 to 80 mg orally, did not significantly alter resting heart rate or blood pressure. In doses less than 40 mg the reduction in exercise…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Celiprolol! A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris by RIDDELL, J. G, SHANKS, R. G, BROGDEN, R. N

    Published in Drugs (New York, N.Y.) (01-10-1987)
    “…Celiprolol is a new 'cardioselective' beta-adrenoceptor blocking drug with intrinsic sympathomimetic (partial agonist) activity and a weak vasodilating effect…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Dose‐dependent alpha 1‐adrenoceptor antagonist activity of the anti‐ arrhythmic drug, abanoquil (UK‐52,046), without reduction in blood pressure in man by Tham, TC, Guy, S, Shanks, RG, Harron, DW

    Published in British journal of clinical pharmacology (01-04-1992)
    “…1. The dose‐dependency of the alpha 1‐adrenoceptor antagonist activity of the anti‐arrhythmic abanoquil (UK‐52,046) was investigated in 10 healthy male…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Effects of the myocardial-selective alpha 1-adrenoceptor antagonist UK-52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs by Uprichard, A G, Harron, D W, Wilson, R, Shanks, R G

    Published in British journal of pharmacology (01-12-1988)
    “…1. Adrenaline-induced arrhythmias in anaesthetized dogs respired with halothane were attenuated in 3 groups of 6 dogs by either UK-52046, 3.8 +/- 1.4…”
    Get full text
    Journal Article
  17. 17

    Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug by Kerr, M J, Wilson, R, Shanks, R G

    Published in Journal of cardiovascular pharmacology (01-09-1985)
    “…Pinacidil, a new vasodilator compound, has been shown to lower blood pressure in animals and humans by a direct vasodilator effect. We have studied the effects…”
    Get more information
    Journal Article
  18. 18

    The dose dependency of the alpha‐adrenoceptor antagonist and beta‐ adrenoceptor partial agonist activity of dilevalol and labetalol in man by Tham, TC, McKaigue, JP, Guy, S, Shanks, RG, Riddell, JG

    Published in British journal of clinical pharmacology (01-09-1993)
    “…1. The alpha‐adrenoceptor antagonist, beta 1‐adrenoceptor antagonist and beta 2‐partial agonist activity of dilevalol, a beta‐adrenoceptor antagonist with…”
    Get full text
    Journal Article
  19. 19

    A comparison of the cardiovascular effects of (+)‐sotalol and (+/‐)‐ sotalol following intravenous administration in normal volunteers by Johnston, GD, Finch, MB, McNeill, JA, Shanks, RG

    Published in British journal of clinical pharmacology (01-11-1985)
    “…In a placebo controlled open study in six healthy male volunteers (+)‐ sotalol in the dose range 0.125 mg kg‐1‐2.0 mg kg‐1 intravenously, was found to have…”
    Get full text
    Journal Article
  20. 20

    The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551 by McCaffrey, P M, Riddell, J G, Shanks, R G

    Published in Journal of cardiovascular pharmacology (01-05-1988)
    “…The selectivity of single oral doses of xamoterol, 200 mg, prenalterol, 50 mg, and salbutamol, 8 mg, was compared in eight healthy male volunteers by measuring…”
    Get more information
    Journal Article